Latest news about Hester Biosciences
Hester Biosciences
2,076.40
+17.70(+0.86%)
Company Performance:
View Company Insights1D+0.86%
1M+16.61%
6M+31.84%
1Y+15.03%
5Y-17.91%
More news about Hester Biosciences
19May 26
Hester Biosciences Q4 PAT surges 174%; Board recommends INR 11 dividend for FY26
Hester Biosciences reported strong Q4 and FY26 results with standalone Q4 PAT up 174% to INR 263.84 mn and revenue up 22% to INR 937.13 mn, driven by 41% growth in Poultry Healthcare. Consolidated Q4 PAT surged 974% to INR 165.46 mn, while FY26 consolidated PAT nearly doubled 99% to INR 574.84 mn. The Board recommended a dividend of INR 11 per share for FY26 and approved the re-appointment of Ms. Priya Gandhi as Executive Director for three years.
24Apr 26
Hester Biosciences Files No Encumbrance Declaration by Promoters for FY26
Hester Biosciences Limited filed a regulatory declaration on April 3, 2026, confirming that promoters and promoter group created no encumbrances during FY26 ended March 31, 2026. The declaration was submitted by Mr. Rajiv Gandhi on behalf of the promoter group under SEBI regulations, ensuring compliance with mandatory disclosure requirements for listed companies.
08Apr 26
Hester Biosciences Submits Quarterly Compliance Reports Under SEBI Framework
Hester Biosciences Limited has filed multiple regulatory compliance disclosures with stock exchanges, including confirmation of its non-classification as a Large Corporate under SEBI framework with outstanding long-term borrowing of INR 12.78 crore and CARE BBB+ rating, alongside submission of quarterly securities dematerialisation certificate for the period ended 31 March 2026 under SEBI Depositories Regulations.
20Mar 26
CARE Ratings Downgrades Hester Biosciences Credit Ratings Across All Bank Facilities
CARE Ratings Limited downgraded Hester Biosciences Limited's credit ratings across all bank facilities on 19 March 2026, revising long-term ratings from BBB+ to BBB and short-term ratings from A2 to A3+. The revision was based on audited FY25 financials and unaudited half-year results ended 30 September 2025. The company considers these ratings transitional, citing improvements in operating margins, ROCE ratios, regulatory approvals for new vaccines, and enhanced debt coverage indicators in H1FY26.
11Mar 26
Hester Biosciences Board Approves Rs 92 Million Divestment of TLPL Stake
Hester Biosciences has received board approval to divest its 43.81% stake in subsidiary Texas Lifesciences Private Limited for Rs 92 million to Ticop Life Private Limited. The transaction, approved following Audit Committee recommendations, will end TLPL's subsidiary status while Hester retains 11% equity and continues business relationships.
10Mar 26
Hester Biosciences Completes Postal Ballot Process for CEO Re-appointment with 99.54% Approval
Hester Biosciences successfully concluded the postal ballot process for re-appointing Mr. Rajiv Gandhi as CEO & Managing Director for three years (2026-2029), receiving overwhelming 99.54% shareholder approval. The company submitted comprehensive regulatory documentation to BSE and NSE, including detailed voting results across shareholder categories and scrutinizer's report confirming compliance with all applicable regulations.
30Jan 26
Hester Biosciences Makes Q3 FY26 Earnings Call Recording Available Online
Hester Biosciences Limited has made its Q3 FY26 earnings conference call audio recording available on the company website following the teleconference held on 30 January 2026. The call discussed financial results for the quarter and nine months period ended 31 December 2025, with the recording now accessible to all shareholders and investors in compliance with SEBI disclosure regulations.
23Jan 26
Hester Biosciences Schedules Q3FY26 Results Conference Call for January 30, 2026
Hester Biosciences Limited has scheduled an earnings conference call for January 30, 2026, at 2:00 PM IST to discuss Q3FY26 and nine-month financial results ended December 31, 2025. The call will be represented by CEO Rajiv Gandhi, Executive Director Priya Gandhi, and CFO Ashish Desai, with ICICI Securities coordinating the investor interaction in compliance with SEBI regulations.
20Nov 25
Hester Biosciences Appoints Ashish Desai as New Chief Financial Officer
Hester Biosciences Limited has appointed Mr. Ashish Desai as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective from 20 November 2025. The Board of Directors approved the appointment based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. Mr. Desai, previously the Group Finance Controller at Hester Biosciences, brings over 25 years of experience in finance. He is a Chartered Accountant with expertise in accounting, budgeting, auditing, finance, costing, and taxation. His appointment is expected to strengthen the company's financial leadership and support its strategic objectives in the biosciences sector.
13Nov 25
Hester Biosciences CFO Divyesh Maru to Step Down in November 2025
Hester Biosciences Limited announced the resignation of its Chief Financial Officer, Divyesh Maru, effective November 13, 2025. Maru is leaving to pursue other career interests. The company has a two-year transition period to find a replacement and ensure a smooth handover of financial leadership responsibilities. The resignation was disclosed in compliance with SEBI regulations.
12Nov 25
Hester Biosciences Reports Mixed Q2 Results: Consolidated Profit Surges 71% Despite Revenue Decline
Hester Biosciences Limited announced its Q2 FY26 results, showing a 15% decline in consolidated revenue to INR 709.69 million, but a 71% increase in profit after tax to INR 143.31 million. The Poultry Healthcare Division grew by 18%, while the Animal Healthcare Division saw a 50% decline due to delays in government immunization programs. The company received market authorization for the H9N2 vaccine and implemented cost optimization measures. Hester Africa reported a net profit of INR 48.20 million, while Hester Nepal faced challenges. The company maintains strong market positions in various segments and expects to regain momentum in Animal Healthcare as government programs resume.
04Aug 25
Hester Biosciences Reports Mixed Q1 Results with Strong Africa Turnaround Despite India Business Headwinds
Hester Biosciences reported mixed Q1 results. Standalone revenue declined 14% to INR 63.00 crores, with PAT down 7%, due to delayed government immunization programs. Animal Health division saw a 33% decline, while Poultry Healthcare grew 2%. Consolidated PAT grew over 100%, driven by international performance. Hester Africa achieved a significant turnaround, posting INR 5.00 crores profit on INR 17.00 crores revenue. Management remains optimistic about future growth, expecting institutional demand to normalize and awaiting regulatory clearances for new vaccine launches.
01Aug 25
Hester Biosciences Reports Mixed Q1 Results: Consolidated Profit Surges 131% Despite Standalone Decline
Hester Biosciences Limited reported mixed Q1 results. Consolidated revenue increased 2% to ₹841.05 crore, with net profit surging 131% to ₹172.96 crore. EBITDA margin improved to 31%. Standalone revenue decreased 14% to ₹634.90 crore, with net profit declining 7% to ₹78.38 crore. Animal Healthcare Division faced challenges with a 33% sales decline, while Poultry Healthcare Division grew 2%. Subsidiaries performed well, with Hester Africa showing a significant turnaround. The company remains focused on product diversification and leveraging international infrastructure for future growth.
09May 25
Hester Biosciences Declares Dividend Amidst Q4 Profit Decline
Hester Biosciences announced a ₹7 per share dividend despite a 73.74% drop in Q4 consolidated net profit to ₹13 million. Revenue increased by 4.05% to ₹72 crore, while sales decreased by 5.67%. EBITDA rose 11.29%, but operating profit halved. The company reported a significant increase in other income to ₹8.80 crore, potentially offsetting operational challenges.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,838.30
(+0.74%)
6,743.00
(-0.35%)
4,429.80
(-0.35%)
1,351.80
(-0.27%)
1,070.80
(-0.34%)
2,351.60
(+1.05%)
1,272.10
(+0.36%)
2,414.20
(+0.34%)
1,497.80
(+3.75%)
1,412.90
(+3.22%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
